Viracta Therapeutics's total assets for Q3 2024 were $21.96M, a decrease of -29.90% from the previous quarter. VIRX total liabilities were $28.57M for the fiscal quarter, a -0.27% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.